These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 23982344)
1. Gold complexes inhibit the aggregation of prion neuropeptides. Wang X; He L; Zhao C; Du W; Lin J J Biol Inorg Chem; 2013 Oct; 18(7):767-78. PubMed ID: 23982344 [TBL] [Abstract][Full Text] [Related]
2. Influence of gold-bipyridyl derivants on aggregation and disaggregation of the prion neuropeptide PrP106-126. Zhao C; Wang X; He L; Zhu D; Wang B; Du W Metallomics; 2014 Nov; 6(11):2117-25. PubMed ID: 25273168 [TBL] [Abstract][Full Text] [Related]
3. Palladium complexes affect the aggregation of human prion protein PrP106-126. Wang Y; Feng L; Zhang B; Wang X; Huang C; Li Y; Du W Inorg Chem; 2011 May; 50(10):4340-8. PubMed ID: 21504185 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of human prion neuropeptide PrP106-126 aggregation by hexacoordinated ruthenium complexes. Wang X; Zhang B; Zhao C; Wang Y; He L; Cui M; Zhu X; Du W J Inorg Biochem; 2013 Nov; 128():1-10. PubMed ID: 23911565 [TBL] [Abstract][Full Text] [Related]
5. Regulation of aggregation behavior and neurotoxicity of prion neuropeptides by platinum complexes. Wang X; Cui M; Zhao C; He L; Zhu D; Wang B; Du W Inorg Chem; 2014 May; 53(10):5044-54. PubMed ID: 24787240 [TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of NAMI-A-like ruthenium complexes on prion neuropeptide fibril formation. Wang X; Zhu D; Zhao C; He L; Du W Metallomics; 2015 May; 7(5):837-46. PubMed ID: 25856332 [TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of sesquiterpene lactones on the aggregation and cytotoxicity of prion neuropeptide. Huo Y; Huang X; Wang Y; Zhao C; Zheng T; Du W Biochimie; 2023 Aug; 211():131-140. PubMed ID: 36963557 [TBL] [Abstract][Full Text] [Related]
8. Heat shock protein 104 inhibited the fibrillization of prion peptide 106-126 and disassembled prion peptide 106-126 fibrils in vitro. Liu YH; Han YL; Song J; Wang Y; Jing YY; Shi Q; Tian C; Wang ZY; Li CP; Han J; Dong XP Int J Biochem Cell Biol; 2011 May; 43(5):768-74. PubMed ID: 21296677 [TBL] [Abstract][Full Text] [Related]
9. Molecular determinants of the physicochemical properties of a critical prion protein region comprising residues 106-126. Salmona M; Malesani P; De Gioia L; Gorla S; Bruschi M; Molinari A; Della Vedova F; Pedrotti B; Marrari MA; Awan T; Bugiani O; Forloni G; Tagliavini F Biochem J; 1999 Aug; 342 ( Pt 1)(Pt 1):207-14. PubMed ID: 10432318 [TBL] [Abstract][Full Text] [Related]
10. Roles of Apigenin and Nepetin in the Assembly Behavior and Cytotoxicity of Prion Neuropeptide PrP106-126. Huo Y; Zhao C; Wang Y; Wang S; Mu T; Du W ACS Chem Neurosci; 2024 Jan; 15(2):245-257. PubMed ID: 38133816 [TBL] [Abstract][Full Text] [Related]
11. The role of prion peptide structure and aggregation in toxicity and membrane binding. Rymer DL; Good TA J Neurochem; 2000 Dec; 75(6):2536-45. PubMed ID: 11080207 [TBL] [Abstract][Full Text] [Related]
12. Prion protein fragment 106-126 induces a p38 MAP kinase-dependent apoptosis in SH-SY5Y neuroblastoma cells independently from the amyloid fibril formation. Corsaro A; Thellung S; Villa V; Principe DR; Paludi D; Arena S; Millo E; Schettini D; Damonte G; Aceto A; Schettini G; Florio T Ann N Y Acad Sci; 2003 Dec; 1010():610-22. PubMed ID: 15033801 [TBL] [Abstract][Full Text] [Related]
13. Small stress molecules inhibit aggregation and neurotoxicity of prion peptide 106-126. Kanapathipillai M; Ku SH; Girigoswami K; Park CB Biochem Biophys Res Commun; 2008 Jan; 365(4):808-13. PubMed ID: 18039468 [TBL] [Abstract][Full Text] [Related]
14. Copper and zinc binding modulates the aggregation and neurotoxic properties of the prion peptide PrP106-126. Jobling MF; Huang X; Stewart LR; Barnham KJ; Curtain C; Volitakis I; Perugini M; White AR; Cherny RA; Masters CL; Barrow CJ; Collins SJ; Bush AI; Cappai R Biochemistry; 2001 Jul; 40(27):8073-84. PubMed ID: 11434776 [TBL] [Abstract][Full Text] [Related]
15. The hydrophobic core sequence modulates the neurotoxic and secondary structure properties of the prion peptide 106-126. Jobling MF; Stewart LR; White AR; McLean C; Friedhuber A; Maher F; Beyreuther K; Masters CL; Barrow CJ; Collins SJ; Cappai R J Neurochem; 1999 Oct; 73(4):1557-65. PubMed ID: 10501201 [TBL] [Abstract][Full Text] [Related]
16. Prion peptide 106-126 as a model for prion replication and neurotoxicity. Singh N; Gu Y; Bose S; Kalepu S; Mishra RS; Verghese S Front Biosci; 2002 Apr; 7():a60-71. PubMed ID: 11897566 [TBL] [Abstract][Full Text] [Related]
17. Oxidation reduces the fibrillation but not the neurotoxicity of the prion peptide PrP106-126. Bergström AL; Chabry J; Bastholm L; Heegaard PM Biochim Biophys Acta; 2007 Sep; 1774(9):1118-27. PubMed ID: 17707142 [TBL] [Abstract][Full Text] [Related]
18. Nonspecific prion protein-nucleic acid interactions lead to different aggregates and cytotoxic species. Macedo B; Millen TA; Braga CA; Gomes MP; Ferreira PS; Kraineva J; Winter R; Silva JL; Cordeiro Y Biochemistry; 2012 Jul; 51(27):5402-13. PubMed ID: 22691027 [TBL] [Abstract][Full Text] [Related]
19. Structural diversity and initial oligomerization of PrP106-126 studied by replica-exchange and conventional molecular dynamics simulations. Ning L; Guo J; Bai Q; Jin N; Liu H; Yao X PLoS One; 2014; 9(2):e87266. PubMed ID: 24586266 [TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity of prion protein peptide (PrP106-126) differs in mechanism from the cytotoxic activity of the Alzheimer's disease amyloid peptide, A beta 25-35. Hope J; Shearman MS; Baxter HC; Chong A; Kelly SM; Price NC Neurodegeneration; 1996 Mar; 5(1):1-11. PubMed ID: 8731376 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]